ADMA Biologics (ADMA) Projected to Post Earnings on Wednesday

Key Points

• ADMA Biologics is scheduled to report Q1 2026 results after the close on Wednesday, May 6, 2026 (conference call 4:30 PM ET); analysts expect $0.195 EPS and $142.744 million in revenue.
• In its most recent quarter (reported Feb. 25) ADMA posted $0.20 EPS (in line with estimates) and $139.16 million in revenue, up 18.4% year‑over‑year with a 28.8% net margin.
• Analyst coverage is generally positive — the consensus rating is Buy with an average target of $25.67, though some firms (e.g., Mizuho) have trimmed price targets.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) is anticipated to release its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect ADMA Biologics to post earnings of $0.1950 per share and revenue of $142.7440 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.20. The business had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The business's revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.46 earnings per share. On average, analysts expect ADMA Biologics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Price Performance

Shares of ADMA opened at $10.90 on Wednesday. The firm has a market capitalization of $2.60 billion, a PE ratio of 18.17 and a beta of 0.82. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $24.48. The company's fifty day moving average price is $12.73 and its 200-day moving average price is $15.64.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ADMA. Mizuho dropped their price objective on shares of ADMA Biologics from $30.00 to $24.00 and set an "outperform" rating on the stock in a report on Monday, April 13th. Wall Street Zen upgraded shares of ADMA Biologics from a "hold" rating to a "buy" rating in a research report on Sunday. Canaccord Genuity Group began coverage on shares of ADMA Biologics in a research report on Monday, April 20th. They issued a "buy" rating and a $21.00 price objective for the company. Cantor Fitzgerald restated a "neutral" rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Finally, Zacks Research upgraded shares of ADMA Biologics from a "hold" rating to a "strong-buy" rating in a research report on Monday, March 2nd. Three research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $25.67.

Insider Buying and Selling

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the transaction, the chief operating officer owned 466,600 shares of the company's stock, valued at approximately $7,292,958. This trade represents a 2.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Steve Elms acquired 7,000 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were bought at an average cost of $15.67 per share, with a total value of $109,690.00. Following the transaction, the director directly owned 2,038,730 shares in the company, valued at $31,946,899.10. This trade represents a 0.34% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 3.70% of the company's stock.

Hedge Funds Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lido Advisors LLC raised its holdings in shares of ADMA Biologics by 3.8% in the 4th quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company's stock valued at $312,000 after purchasing an additional 629 shares in the last quarter. Cim LLC raised its stake in ADMA Biologics by 0.7% during the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company's stock worth $1,341,000 after acquiring an additional 665 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in ADMA Biologics by 28.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 700 shares in the last quarter. Cerity Partners LLC grew its position in ADMA Biologics by 1.8% during the 2nd quarter. Cerity Partners LLC now owns 48,572 shares of the biotechnology company's stock worth $884,000 after purchasing an additional 869 shares during the last quarter. Finally, Fieldview Capital Management LLC grew its position in ADMA Biologics by 7.3% during the 4th quarter. Fieldview Capital Management LLC now owns 21,708 shares of the biotechnology company's stock worth $396,000 after purchasing an additional 1,486 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.